Piramal Pharma shares jumped more than 4% in morning trade after the company reported strong Q2 FY25 results.
Revenue from operations increased by 17% YoY to ₹2,242 crore from ₹1,911 crore in Q2 FY24, with significant success in the CDMO segment. EBITDA increased by 28% YoY to ₹403 crore, with an EBITDA margin of 18%, up 150 basis points. PAT (Profit After Tax) is ₹23 crore, up 350% YoY from ₹5 crore in Q2 FY24. PAT Margin is 1%, compared to 0% in the previous year.
As of 9:16 am, Piramal Pharma shares were trading 3.90% higher at Rs 226.34 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
